An interventional study of Palatable Elemental Diet in Chronic Pancreatitis, sponsored by Stanford University. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
Study withdrawn prior to participant enrollment because funding was not available to initiate the study.
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies in Pancreatitis, Chronic with a site in United States — 27 open to participants now, 38 under way, none of them phase 3. Pancreatitis, Chronic · United States.
Among the 111 studies in Pancreatitis, Chronic with a site in United States, this one is the 67th largest by enrollment of the 73 interventional ones that give a count, is one of 8 that started in 2026, is one of 32 with no phase, and was the 108th registered.
266 studies on the registry are indexed under Pancreatitis, Chronic; 76 are open to participants now.
Browse Pancreatitis, Chronic studies →27 of the 111 studies in Pancreatitis, Chronic with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Orlando Health, Inc. · Sites in United States
Ages 18+
Anna Evans Phillips · Sites in United States
Ages 18+
Ohio State University · Sites in United States
Ages 18–80
Mayo Clinic · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 49 Pancreatitis, Chronic studies recruiting now, 31 (63%) set no upper age limit and 12 (24%) stop at 75 or younger; 8 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 15 · Phase 3 7 · Phase 4 6
First in 2000; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 32 across the 73 interventional studies, 167 across the 38 observational. Of the 63 that completed or were terminated, 23 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 111 have an industry lead sponsor. The 10 most frequent:
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Stanford University has 2 studies filed under Pancreatitis, Chronic — fewer than ten, so there is no comparison to draw.
16 of the studies in Pancreatitis, Chronic with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03097185Baylor Research InstituteAnalysis of Graft Function Following Autologous Islet Transplantation | 2026-12 |
| NCT07174609Johns Hopkins UniversityScrambler Therapy in Chronic Pancreatitis | 2026-12-01 |
| NCT05925036VA Office of Research and DevelopmentNovel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis | 2026-12-31 |
| NCT06651580M.D. Anderson Cancer CenterBiospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | 2027-02-02 |
| NCT07285863Mayo ClinicA Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects | 2027-03 |
Add all 16 to your calendar (.ics) → With an account.
Among the 111 studies in Pancreatitis, Chronic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether a 2-week exclusive palatable elemental diet is feasible, tolerable, and acceptable for adults with chronic pancreatitis and bothersome gastrointestinal symptoms. An elemental diet is a nutritionally complete formula made from ingredients that are easy to absorb. The main questions it aims to answer are whether participants can complete the diet as planned, and whether they can take in most of the prescribed formula, and how acceptable the study diet is to participants at the end of the 2-week diet period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this single-arm study will consume an exclusive oral palatable elemental diet for 14 days. During the intervention period, participants will complete daily diet and symptom diaries and undergo study assessments, including questionnaires and biospecimen collection. After the 14-day diet period, participants will resume their usual diet and continue follow-up for 4 additional weeks.
Other: Palatable Elemental Diet
The intervention is an exclusive oral palatable elemental diet administered for 14 consecutive days as the participant's sole nutritional intake. This amino acid-based formula was developed to provide an elemental diet with improved palatability and tolerability. Following completion of the 14-day diet period, participants will return to their usual diet and undergo 4 additional weeks of follow-up.
Also known as: Elemental Diet, Exclusive Oral Palatable Elemental Diet
Number of Participants Who Complete at Least 12 of 14 Days of the Palatable Elemental Diet
Completion is defined as completing at least 12 of the 14 study diet days during the exclusive palatable elemental diet period. The feasibility target is that at least 80% of participants meet this criterion.
Time frame: During the 14-day exclusive palatable elemental diet period (Day 14 to Day 28)
Number of Participants Who Consume at Least 75% of Prescribed Palatable Elemental Diet Calories
Diet adherence is defined as consuming at least 75% of prescribed palatable elemental diet calories during the 14-day exclusive diet period, based on daily diary tracking. The feasibility target is that at least 75% of participants meet this criterion.
Time frame: During the 14-day exclusive palatable elemental diet period (Day 14 to Day 28)
Participant-Reported Acceptability of the Palatable Elemental Diet
Acceptability will be assessed using participant-reported questionnaire items completed at Day 28. Items will assess organoleptic acceptability of the study diet, including appearance, smell, taste, aftertaste, and consistency, as well as overall acceptability. Responses will be summarized descriptively.
Time frame: Day 28, after completion of the 14-day exclusive palatable elemental diet period
Change From Baseline in Structured Assessment of Gastrointestinal Symptoms Global Symptom Burden Score
Structured Assessment of Gastrointestinal Symptoms total score. The instrument uses 22 Likert-scale questions to calculate total gastrointestinal symptom burden, with a total score range of 0 to 88. Higher scores indicate worse gastrointestinal symptom burden.
Time frame: Baseline, Day 28, and Day 56
Change From Baseline in Patient-Reported Outcomes Measurement Information System Global Health Version 1.2 (PROMIS Global Health v1.2) Summary Score
PROMIS Global Health v1.2 summary score derived from the 10-item questionnaire administered at study visits. The instrument assesses general, physical, mental, and social health, including physical function, emotional problems, fatigue, and pain. Nine items use 5-point response scales and 1 pain item uses a 0-to-10 scale. Higher scores indicate better global health overall.
Time frame: Baseline, Day 28, and Day 56
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Jul 2028, 23 months later.
How these figures are worked out, and which studies are left out of them.
Study withdrawn prior to participant enrollment because funding was not available to initiate the study.
Study withdrawn prior to participant enrollment because funding was not available to initiate the study.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.